Peptides for women: what is studied and what is not

Where the peptide research includes women, where it does not, how cycle phase and menopause change the questions worth asking, and what to measure before starting anything.

Key takeaways

One peptide is FDA approved specifically for women: bremelanotide, for hypoactive sexual desire disorder in premenopausal women.
The GLP-1 obesity trials were majority female, so that is the peptide category with the most direct evidence in women.
The repair peptides most discussed online, BPC-157 and TB-500, have no completed human trials in either sex, and that is the honest starting point for both men and women.
Growth hormone regulation differs by sex, which is a reason to interpret IGF-1 against the right reference range rather than a reason to assume peptides work differently.
Anyone who could become pregnant needs the pregnancy question answered before starting, and for GLP-1 medicines that includes stopping well before a planned conception.
The practical answer is the same as it is for men, with less published data to lean on: measure first, then decide.

Almost every peptide conversation online is written for men, and the dosing anecdotes circulating in forums come from men.

The biology is not identical, the trial evidence in women is thinner, and both of those facts are worth saying out loud before anyone starts.

Start with the gap, not the pitch

Most peptide content online is written for men, and much of the dosing folklore circulating in forums comes from male users describing male outcomes. That matters less for some peptides than people assume, and more for others than the marketing admits.

The useful way to sort this is by evidence tier rather than by whether a product is marketed to women. Some of these have randomized trials that enrolled thousands of women. Some have mechanism and animal work and nothing else. Both can be worth considering. They are not the same conversation, and being told which one you are in is the difference between an informed decision and a purchase.

Where the evidence in women is strongest

Everything below this line has thinner evidence, and in some cases none in humans. That is not an argument against the biology. It is an argument for knowing where you stand.

GLP-1 and dual agonist medicines. The large weight management trials enrolled mostly women, roughly three quarters of participants in STEP 1 and about two thirds in SURMOUNT-1, so the published outcomes are substantially female data rather than an extrapolation.
Bremelanotide, the peptide known as PT-141. It was studied in and approved for premenopausal women with acquired, generalized hypoactive sexual desire disorder, in trials enrolling well over a thousand women. It is the one peptide in this space whose primary evidence base is female.
Tesamorelin, approved for a specific condition, HIV associated lipodystrophy, in trials that included women.

Where the evidence is mechanism, not outcomes

Mechanism is not worthless. It is how most therapies begin, and for people whose conventional options have already failed it is often the reason they are here. It should just be labeled honestly, and the expectation set accordingly.

BPC-157 and TB-500. Extensive animal work on tendon, ligament, gut and soft tissue healing, no completed published human trials. This applies equally to men.
MOTS-c. A real mitochondrial peptide with interesting metabolic findings in animals and exercise physiology, without published human randomized trials.
KPV. Anti-inflammatory mechanism, preclinical work in gut inflammation, no human trial evidence.
Growth hormone secretagogues such as sermorelin and CJC-1295 with ipamorelin. These reliably raise growth hormone and IGF-1. What is less established is which clinical outcomes that produces in healthy adults, in either sex.
GHK-Cu, mainly studied topically for skin, where the cosmetic literature is more developed than the injectable one.

What genuinely differs in women

Growth hormone regulation. Sex steroids modulate GH secretion and the IGF-1 response to it, which is why IGF-1 should be read against an age and sex specific reference range rather than a single number someone quotes online.
Thyroid disease is meaningfully more common in women, and its symptoms overlap almost completely with the fatigue and body composition complaints that bring people to peptides. That is a reason to check thyroid function before assuming a peptide is the answer.
Iron status. Low ferritin from heavy periods is a common and correctable cause of fatigue, hair shedding and poor exercise tolerance. It is also frequently missed before someone starts something more exotic.
The menopause transition changes the muscle, bone and cardiometabolic picture in a way that changes which goals are realistic and which markers to watch.
Body size. Fixed doses copied from a man twice your weight are a bad starting point, which is one of the reasons dosing decisions belong with a licensed provider and not a forum.

The pregnancy question, which comes first

For anyone who could become pregnant, this is not a footnote. Peptides in this space have not been studied in pregnancy, and for GLP-1 receptor agonists the labeling directs discontinuation well in advance of a planned pregnancy, two months in the case of semaglutide for weight management, because of the drug's long duration in the body.

Weight loss medicines can also improve ovulatory function in some people, which means fertility may return faster than expected. Contraception and pregnancy planning belong in the first conversation, not a later one.

What to measure before starting anything

A full blood count with ferritin, because iron deficiency is the most common correctable cause of the symptoms people bring here.
TSH with free T4.
Fasting insulin and glucose for HOMA-IR, plus HbA1c.
A lipid panel with ApoB, and Lp(a) once.
25-hydroxyvitamin D.
IGF-1 if a growth hormone peptide is being considered, read against an age and sex matched range.
Estradiol, FSH and other hormone testing where symptoms and cycle history warrant it, interpreted with the clinical picture rather than alone.
Body composition, ideally DEXA, because the scale conceals the muscle to fat shift that most of these goals are really about.

How this works here

Baseline is a wellness consultancy. An independent licensed physician reviews your intake, your history and your labs and decides what, if anything, is appropriate and at what dose. Nothing is dispensed from a page like this one, and we do not publish reader facing dose numbers.

If you want to know which of these categories fits your situation, a consult is the shortest path, and the labs above are what makes that conversation specific rather than generic.

What this means for you

There is real evidence for women in the metabolic and sexual health peptides, and mechanism without human outcomes in the repair and longevity ones. Get iron, thyroid, metabolic and lipid markers on paper first, settle the pregnancy question, then have the conversation with a provider who is reading your numbers.

Therapies discussed here

References

Wilding JPH, et al., once weekly semaglutide in adults with overweight or obesity (STEP 1), New England Journal of Medicine, 2021
Jastreboff AM, et al., tirzepatide once weekly for the treatment of obesity (SURMOUNT-1), New England Journal of Medicine, 2022
Kingsberg SA, et al., bremelanotide for the treatment of hypoactive sexual desire disorder, two randomized phase 3 trials (RECONNECT), Obstetrics and Gynecology, 2019
Falutz J, et al., metabolic effects of a growth hormone releasing factor in patients with HIV, New England Journal of Medicine, 2007
Giustina A, Veldhuis JD, pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human, Endocrine Reviews, 1998
Wegovy (semaglutide) prescribing information, Novo Nordisk, current label
Camaschella C, iron deficiency, Blood, 2019
Chang CH, et al., the promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival and cell migration, Journal of Applied Physiology, 2011
The Menopause Society, 2022 hormone therapy position statement, Menopause, 2022